|
|
| | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Basic information |
| Product Name: | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] | | Synonyms: | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate];9-Fluoro-11β,17-dihydroxy-16β-methyl-21-[tricyclo[3.3.1.13,7]decan-1-ylcarbonyloxy]pregna-1,4-diene-3,20-dione | | CAS: | 40242-27-1 | | MF: | C33H43FO6 | | MW: | 554.695 | | EINECS: | 254-855-1 | | Product Categories: | | | Mol File: | 40242-27-1.mol | ![9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Structure](CAS/GIF/40242-27-1.gif) |
| | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Chemical Properties |
| | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Usage And Synthesis |
| Originator | Betamethasone,Zhejiang Xianju
Pharmaceutical
Co., Ltd. | | Manufacturing Process | 3 Methods of producing of betamethasone 21-adamantane-1'-carboxylate:
1. A suspension of betamethasone (740.0 mg) in dioxan (20 ml) was treated
with adamantane carboxylic acid (1.96 g) and trifluorcacetic anhydride (0.75
ml). The mixture was stirred at room temperature for 23 h during which time
the steroid completely dissolved. Addition of sodium bicarbonate (2.0 g) and
water gave a waxy semi-solid which was separated from the supernatant
liquid by decantation. Water and a little methanol were added to the solid and
the resulting granular material was removed by filtration and washed well with
water. Fractional crystallization from methanol afforded adamantane carboxylic
anhydride as the less soluble component and betamethasone 21-adamantane-
1'-carboxylate as the more soluble component.
2. 9α-Fluoro-11β,17-dihydroxy-21-iodo-16β-methylpregna-1,4-diene-3,20-
dione (76.65 g) was dissolved in warm acetone (400 ml) and then
adamantanecarboxylic acid (54.0 g) and triethylamine (52.5 ml) was added
and washed in with more acetone (100 ml). The solution was refluxed for 1 h
and then poured with good stirring into cold water (2.5 L). Filtration of the
precipitated material and recrystallisation from aqueous methanol with
charcoaling afforded betamethasone 21-admantane-1'-carboxylate showing
extensive melting 245°-250°C.
3. A solution of betamethasone (1.0 g) in dry tetrahydrofuran (40 ml) was
treated with adamantane carbonyl chloride (about 2.2 equivalents) in dry
tetrahydrofuran (5 ml) and then pyridine (0.8 ml) was added. The mixture
was refluxed for 6 h and then most of the solvent was boiled off and the
residue extracted with chloroform to afford a froth. The ether soluble portion
of this froth was dissolved in chloroform and extracted repeatedly with dilute
sodium bicarbonate solution. Evaporation of the chloroform layer gave a froth
which was further purified by chromatography and crystallisation from
chloroform-petroleum ether to yield betamethasone 21-adamantane-1'-
carboxylate melting point 256°-259°C (dec.). | | Therapeutic Function | Glucocorticoid |
| | 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Preparation Products And Raw materials |
|